AbDrop™: Fully Human Antibodies Discovery: Increased Diversity, Validated Candidates in Just 3 Months! LEARN MORE

New Small-Scale Expression Packages: RushMab- Ready in just 8 days! LEARN MORE

Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis) LEARN MORE

Biointron - Antibody Discovery, Antibody Production, Stable cell line, Protein Expression, CRO

Antibody Antibody Antibody

Services & Products

About Us

  • 0 +
    Years of Experience
  • 0 +
    Employees
  • 0 +
    Companies Served Globally
  • 0 +
    Delivered Annually

Why you should choose us

  • Pioneering Antibody Solutions

    We specialize in antibody expression, discovery, and optimization with internationally recognized automated production standards - offering superior services at market- competitive rates with efficient turnaround times.

  • Unique Cell Line Commercialization

    We possess exclusive re-licensing rights for the commercialization of the CHO-K1BN cell line licensed from ECACC.

  • Global Collaborative Excellence

    Our partnerships with 2,000+ global biotech and pharmaceutical entities, coupled with our collaborative advancements in international clinical stages, solidify our esteemed position in the industry.

  • Trust and Exclusive Ownership

    We commit to complete confidentiality - preserving the exclusive ownership rights of the antibodies we produce for our clients.

Antibody

Engage with Biointron, your dependable partner for efficient, affordable, and top-tier custom antibody solutions.

About Biointron

Founded in 2012, and certified to ISO 9001:2015, Biointron is a CRO (Contract research organization) specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.


Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. From gene sequence to purified antibodies, it just takes 2 weeks. Biointron has delivered tens of thousands of recombinant antibodies for 2,000+ biotech and pharma companies all over the world.

Read More Read More

Client Voices: Biointron Success Stories

Learn from our partners and clients about the transformative impact of Biointron's expertise.

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

Our Latest News and Stories

Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis)

Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March).

Mar 31, 2025
Biointron’s 2025 Lunch & Learn Antibody Series: “Advancing Antibody Discovery: Innovations, Trends, and Industry Insights”

Biointron’s Lunch & Learn with MassBio was held in Boston, MA, on May 9. The session focused on the advancements in antibody discovery in the biopharma industry and featured three key speakers: Dr. Hitesh Soni (Director of In Vivo Pharmacology at Tectonic Therapeutic Inc.), Dr. Lei Shi. (SVP at

May 12, 2025
AI-Driven Antibody Therapeutics: From Data to Design

The Evolution from Traditional Methods to AI-Enhanced Antibody EngineeringAntibody discovery has historically relied on experimental platforms such as phage display, yeast display, and animal immunization. The integration of computational biology in the late 20th century is overcoming biological lim

May 05, 2025
Biointron Launches a Fast Antibody Discovery Platform

Introducing a new High-throughput Fully Humanized Antibody Discovery Platform with Biointron AbDrop & Cyagen HUGO-Ab! This novel approach combines microfluidic technology for single B cell antibody discovery and fully human antibody mice for a safer and more efficient approach for fully human antibody discovery​, ready in as quickly as 3 months.

Mar 07, 2025
Biointron Recognized with 2024 Scientist.com Supplier Performance Recognition Award!

Biointron is proud to share that we have received the 2024 Scientist.com Supplier Performance Recognition Award, for our dedication to providing high-quality drug discovery research services on this industry-renowned R&D sourcing platform.

Feb 07, 2025
Biointron Achieves High Certification in Third-Party Risk Assessment Conducted by CyberVadis

This comprehensive assessment, which evaluated our entire organization and all functions, underscores our commitment to excellence in cybersecurity and risk management. CyberVadis is a leading global provider of independent cybersecurity assessment services, and their rigorous evaluation process includes international standards such as ISO 2700x, NIST Cybersecurity Framework, ICS Cybersecurity, and GDPR.

Aug 05, 2024
BIO KOREA 2025

Time: May 7-9, 2025
Location: Seoul, South Korea

PEGS Summit 2025

Time: May 12-16, 2025
Location: Boston, MA
Booth: #311

Antibody Engineering & Therapeutics Europe 2025

Time: June 10-12, 2025
Location: Basel, Switzerland
Booth: #24

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.